Boston Life Sciences to fund axon regeneration studies

By Lisa Kerner

Erie, Pa., May 11 - Boston Life Sciences, Inc. said it entered into exclusive, worldwide license and research agreements with Children's Hospital Boston for axon regeneration technologies currently under development.

Boston Life Sciences will fund three-year research programs for approaches to activate pro-regenerative pathways that stimulate axon regeneration and to deactivate anti-regenerative pathways that inhibit axon regeneration.

The goal of axon regeneration is to restore functionality lost as a result of injury by reconnecting the neural pathways through new axon growth.

"[Boston Life Sciences] is focused on developing world-class technologies in axon regeneration for functional recovery following severe CNS (central nervous system) injury," president and chief operating officer Mark Pykett said in a company news release.

"We believe that these agreements extend our existing capabilities in axon regeneration by potentially providing multiple avenues for intervention in functional CNS recovery."

Boston Life Sciences is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.